SEC filer · CIK 0000880242 · BLGO
Biolargo, Inc.
Biolargo total assets: $8.31 million at 2025-12-31. Operating cash flow: -$8.30 million for the year ending 2025-12-31.
Every reported measure
The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Total assets | - | 2025-12-31 | $8.31 million | 2026-03-04 |
| Total liabilities | - | 2025-12-31 | $6.79 million | 2026-03-04 |
| Stockholders equity | - | 2025-12-31 | $4.04 million | 2026-03-04 |
| Cash and cash equivalents | - | 2025-12-31 | $3.88 million | 2026-03-04 |
| Operating cash flow | 2025-01-01 | 2025-12-31 | -$8.30 million | 2026-03-04 |
| Financing cash flow | 2025-01-01 | 2025-12-31 | $8.22 million | 2026-03-04 |
| Investing cash flow | 2025-01-01 | 2025-12-31 | $435.0 thousand | 2026-03-04 |
| Retained earnings or deficit | - | 2025-12-31 | -$161.3 million | 2026-03-04 |
| Basic weighted-average shares | 2025-01-01 | 2025-12-31 | 307.0 million shares | 2026-03-04 |
| Basic earnings per share | 2025-01-01 | 2025-12-31 | -$0.04 per share | 2026-03-04 |
| Net property, plant and equipment | - | 2025-12-31 | $1.64 million | 2026-03-04 |
| Share-based compensation expense | 2025-01-01 | 2025-12-31 | $2.96 million | 2026-03-04 |
| Operating income or loss | 2025-01-01 | 2025-12-31 | -$14.9 million | 2026-03-04 |
| Current assets | - | 2025-12-31 | $5.11 million | 2026-03-04 |
| Current liabilities | - | 2025-12-31 | $5.06 million | 2026-03-04 |
| Current accounts payable | - | 2025-12-31 | $1.01 million | 2026-03-04 |
| Net current accounts receivable | - | 2025-12-31 | $615.0 thousand | 2026-03-04 |
| Operating expenses | 2025-01-01 | 2025-12-31 | $18.3 million | 2026-03-04 |
| Net inventory | - | 2025-12-31 | $310.0 thousand | 2026-03-04 |
| Gross profit | 2025-01-01 | 2025-12-31 | $3.41 million | 2026-03-04 |
| Selling, general and administrative expense | 2025-01-01 | 2025-12-31 | $11.8 million | 2026-03-04 |
| Research and development expense | 2025-01-01 | 2025-12-31 | $2.59 million | 2026-03-04 |
| Additional paid-in capital | - | 2025-12-31 | $165.3 million | 2026-03-04 |
| Accumulated other comprehensive income or loss | - | 2025-12-31 | -$207.0 thousand | 2026-03-04 |
| Total equity including noncontrolling interests | - | 2025-12-31 | $1.53 million | 2026-03-04 |
| Operating lease right-of-use asset | - | 2025-12-31 | $1.03 million | 2026-03-04 |
| Operating lease liability | - | 2025-12-31 | $1.07 million | 2026-03-04 |
| Long-term debt | - | 2025-12-31 | $2.08 million | 2026-03-04 |
| Gross property, plant and equipment | - | 2025-12-31 | $2.25 million | 2026-03-04 |
| Accumulated depreciation on property, plant and equipment | - | 2025-12-31 | $607.0 thousand | 2026-03-04 |
| Other noncurrent assets | - | 2025-12-31 | $106.0 thousand | 2026-03-04 |
| Prepaid expenses and other current assets | - | 2025-12-31 | $306.0 thousand | 2026-03-04 |
| Current contract liabilities | - | 2025-12-31 | $280.0 thousand | 2026-03-04 |
| Profit or loss including noncontrolling interests | 2025-01-01 | 2025-12-31 | -$15.2 million | 2026-03-04 |
| Comprehensive income or loss | 2025-01-01 | 2025-12-31 | -$11.8 million | 2026-03-04 |
| Net income available to common stockholders | 2025-01-01 | 2025-12-31 | -$11.8 million | 2026-03-04 |
| Depreciation expense | 2025-01-01 | 2025-12-31 | $145.0 thousand | 2026-03-04 |
| Nonoperating income or expense | 2025-01-01 | 2025-12-31 | -$334.0 thousand | 2026-03-04 |
| Interest paid, net | 2025-01-01 | 2025-12-31 | $344.0 thousand | 2026-03-04 |
| Proceeds from issuing common stock | 2025-01-01 | 2025-12-31 | $2.03 million | 2026-03-04 |
| Change in accounts receivable | 2025-01-01 | 2025-12-31 | $1.81 million | 2026-03-04 |
| Change in inventories | 2025-01-01 | 2025-12-31 | -$20.0 thousand | 2026-03-04 |
Older measures: 8 not reported in the two years before 2026-09-20
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Net income or loss | 2014-01-01 | 2014-12-31 | -$3.69 million | 2015-03-31 |
| Revenue | 2023-01-01 | 2023-12-31 | $12.2 million | 2024-04-01 |
| Interest expense | 2023-01-01 | 2023-12-31 | $91.0 thousand | 2024-04-01 |
| Net finite-lived intangible assets | - | 2021-12-31 | $3.02 million | 2023-03-31 |
| Cost of revenue | 2018-01-01 | 2018-12-31 | $743.0 thousand | 2019-03-29 |
| Common shares outstanding | - | 2023-12-31 | 292.9 million shares | 2024-04-01 |
| Depreciation, depletion and amortization | 2018-01-01 | 2018-12-31 | $50.0 thousand | 2019-03-29 |
| Other nonoperating income or expense | 2023-01-01 | 2023-12-31 | -$68.0 thousand | 2024-04-01 |
Filings
- 10-Q filed 2026-08-14
- 10-Q filed 2026-05-15
- 10-K filed 2026-03-04
- 10-Q filed 2025-11-14
- 10-Q filed 2025-08-14
61 Biolargo filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.
Inspect the source
- Entity
- BIOLARGO, INC. / CIK 0000880242
- Captured
- SEC response SHA-256
b9a8cfafd56ec81d001e21388dc4ce638c4b85e57aee741072b78336d74598c0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000880242.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))